COMMUNIQUÉS West-GlobeNewswire

Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
12/04/2024
Company will host investor call on April 17 at 8:00 a.m. ET to discuss new data from GTX-102 Phase 1/2 clinical study in patients with Angelman syndrome NOVATO, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Ultragenyx [...]
Notable Labs Reports 2023 Financial Results and Provides a Business Update
12/04/2024
FOSTER CITY, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing new cancer therapies identified by its [...]
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
12/04/2024
In a preliminary review of blinded data from the ongoing TREK-DX study, 45% (10/22) of patients achieved at least a 90% reduction in their EASI score (EASI-90) after 16 weeks. 56% (5/9) of patients with prior inadequate [...]
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
12/04/2024
MALVERN, Pa., April 12, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, [...]
Invivyd Announces CEO Transition
12/04/2024
Jeremy Gowler appointed Interim CEO WALTHAM, Mass., April 12, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious [...]
BioSenic provides further information on its restructuring plan
12/04/2024
PRESS RELEASE - PRIVILEGED INFORMATION Mont-Saint-Guibert, Belgium, 12 April 2024, 12:00 CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory [...]
BioSenic fournit des informations complémentaires sur son plan de restructuration
12/04/2024
COMMUNIQUE DE PRESSE – INFORMATION PRIVILEGIEE Mont-Saint-Guibert, Belgique, le 12 avril 2024 à 12h00 CET – BIOSENIC (Euronext Bruxelles et Paris: BIOS), la société en phase clinique spécialisée dans les maladies auto- [...]
RadNet Teams Up with Basketball Icon Sheryl Swoopes to Promote Healthcare Equity and Access
12/04/2024
First Initiative Spotlights Breast Cancer Screening Services Inside Walmart LOS ANGELES, April 12, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective [...]
Oncocyte Reports Full Year 2023 Financial Results
12/04/2024
Conference Call on Friday, April 12, 2024 at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial [...]
T-cell therapy developer, Cbio A/S Unveils 2023 Annual Report Amid Clinical Trial Preparations, Signaling Major Shift to Clinical Stage with DKK40M Financing Secured
12/04/2024
SØBORG, Denmark, April 12, 2024 (GLOBE NEWSWIRE) -- Cbio A/S – Pioneering Next-Gen T-Cell Therapies for Solid Tumors, Unveils 2023 Financial Results and Company Updates. Ulrik Cordes, Founder & CEO of Cbio, stated [...]
Fagron publishes agenda for 2024 annual shareholders meeting and extraordinary general meeting
12/04/2024
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 12 April 2024 – 8AM CET Fagron publishes agenda for 2024 annual shareholders meeting and extraordinary general meeting The Board of Directors of [...]
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
12/04/2024
SAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the pricing of its upsized underwritten public offering of 10,166,667 shares of its common stock at a price to [...]
UPDATE: Predicine Introduces PredicineCARE™ NGS Kit for Tumor Profiling
12/04/2024
HAYWARD, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc., a leading molecular insights company, announced the release of its innovative PredicineCARE™ NGS Kit. This offering presents a research-use-only (RUO [...]
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
12/04/2024
IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a precision diagnostics company, today announced that it has entered into definitive securities [...]
Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay
11/04/2024
- Bio-Rad expects to make equity investment in support of deal - Agreement provides for global exclusivity in transplant monitoring commercialization - Bio-Rad granted subsequent investment option upon FDA clearance [...]
Longeveron Announces Closing of $5.2 Million Public Offering
11/04/2024
MIAMI, April 11, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging- [...]
Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer
11/04/2024
Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer Mont-Saint-Guibert, Belgium – April 11, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical [...]
Nyxoah Nomme le Dr Maurits S. Boon, MD, au Poste de Chief Medical Officer
11/04/2024
Nyxoah Nomme le Dr Maurits S. Boon, MD, au Poste de Chief Medical Officer Mont-Saint-Guibert, Belgique – 11 avril 2024, 22h30 CET / 16h30 ET – Nyxoah SA (Euronext Bruxelles/Nasdaq : NYXH) (« Nyxoah » ou la « Société ») [...]
PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission
11/04/2024
TARRYTOWN, New York, April 11, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica , Inc. (NASDAQ: PXMD ), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the completed [...]

Pages